Treatment of graft failure with fludarabine (Flu), antithymocyte globulin (ATG) and a second allogeneic stem cell transplantation (SCT).

被引：0
|
作者：
Jabbour, EJ [1 ]
Shahjahan, M [1 ]
Rondon, G [1 ]
Anderlini, P [1 ]
Giralt, S [1 ]
Couriel, DR [1 ]
Champlin, RE [1 ]
Khouri, IF [1 ]
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2734
引用
收藏
页码：767A / 767A
页数：1
相关论文
共 50 条
  • [31] Treatment of donor graft failure with autologous or allogeneic stem cell boost or a second allogeneic transplantation based on chimerism testing
    Shimoni, A.
    Shem-Tov, N.
    Rand, A.
    Ribakovsky, E.
    Yerushalmi, R.
    Hardan, I.
    Nagler, A.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S10 - S10
  • [32] NKT cell predicts the severity of acute graft-versus-host disease in patients after allogeneic stem cell transplantation using antithymocyte globulin(ATG) in pretreatment scheme
    Zhang, P.
    Yan, X.
    Zhang, Y.
    Wu, H.
    Sun, Y.
    Zhou, M.
    Mu, Q.
    Shi, C.
    Zhu, H.
    Sheng, L.
    Xu, K.
    Wang, Y.
    Ouyang, G.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1500 - 1501
  • [33] Antithymocyte Globulin for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation
    Mohty, Mohamad
    Malard, Florent
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (36) : 3993 - +
  • [34] Cytomegalovirus (CMV) infection in patients receiving either alemtuzumab (Campath I-H) or antithymocyte globulin (ATG) as graft-versus-host disease (GVHD) prophylaxis prior to allogeneic stem cell transplantation (SCT)
    Hunt, WG
    May, GR
    Krance, RA
    Heslop, HE
    Catherine, B
    Kuehnle, I
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (02) : 37 - 37
  • [35] Mini-review - Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation
    Wolff, SN
    BONE MARROW TRANSPLANTATION, 2002, 29 (07) : 545 - 552
  • [36] Antithymocyte globulin in pediatric allogeneic hematopoietic stem cell transplantation: Infusion time and tolerability
    Sevrin, Francois
    Gonzales, Fanny
    Machuron, Francois
    de Berranger, Eva
    Bruno, Benedicte
    PEDIATRIC TRANSPLANTATION, 2020, 24 (04)
  • [37] Allogeneic stem cell transplantation (SCT) for patients (pts) with Thalassemia major: An inferior outcome when antithymocyte globlins (ATG) is added to the conditioning regimen
    Al-Jefri, A
    Ayas, M
    Al-Musa, A
    Al-Mahr, M
    Al-Fawaz, I
    Saleh, M
    Sabbah, R
    Moussa, E
    Khairy, A
    El-Solh, H
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (02) : 9 - 9
  • [38] Fludarabine (Flu) and IV busulfan (Bu)±ATG:: Low toxicity conditioning regimen for stem cell transplantation (SCT) in AML and MDS -: Preliminary results.
    deLima, M
    Shahjahan, M
    Madden, T
    Tran, HT
    Gajewski, JL
    Couriel, DR
    Giralt, S
    Donato, ML
    Anderlini, P
    Korbling, M
    Khouri, I
    Russell, JA
    Champlin, RE
    Andersson, BS
    BLOOD, 2001, 98 (11) : 345B - 345B
  • [39] Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia
    Anderlini, Paolo
    Acholonu, Sandra A.
    Okoroji, Grace-Julia
    Bassett, Roland E., Jr.
    Shpall, Elizabeth J.
    Qazilbash, Muzaffar H.
    Popat, Uday R.
    Worth, Laura L.
    Giralt, Sergio A.
    Champlin, Richard E.
    LEUKEMIA & LYMPHOMA, 2011, 52 (01) : 137 - 141
  • [40] Fludarabine/melphalan conditioning for allogeneic stem cell transplantation (SCT) in elderly patients with AML/MDS
    Kennedy, GA
    Butler, J
    Durrant, S
    Hill, GR
    Western, R
    Morton, J
    BLOOD, 2005, 106 (11) : 438B - 439B
12345